ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: PO1258

Acute Peritoneal Dialysis in Obese Patients During the COVID-19 Pandemic

Session Information

Category: Dialysis

  • 703 Dialysis: Peritoneal Dialysis


  • Joseph, Leian, NYU Langone Health, New York, New York, United States
  • Ranjeeta, Fnu, NYU Langone Health, New York, New York, United States
  • Caplin, Nina J., NYU Langone Health, New York, New York, United States
  • Amerling, Richard, Bellevue Hospital Center, New York, New York, United States

Due to increased risk for infection, fluid leak, metabolic complications and poor uremic solute clearance, concerns have been raised in using peritoneal dialysis in obese patients. However, due to unprecedented need for renal replacement therapy (RRT) in New York City during the COVID-19 pandemic, acute peritoneal dialysis (APD) was initiated in patients regardless of body mass index (BMI).


36 patients who received PD between April 8, 2020 and May 8,2020 were categorized into 3 groups based on BMI calculated using admission height and weight. Group 1 with BMI < 30, Group 2 with BMI 30-40 and Group 3 with BMI > 40 kg/m2.
Treatment goals included correction of hyperkalemia, hyperphosphatemia, acid-base abnormalities, reduction in blood urea nitrogen (BUN), creatinine and maintaining euvolemia. All patients were initially started on manual exchanges every 1-2 hours (Total volume 10-13L/24 hours) and eventually most were changed to automated PD (Total volume 18-20L/24 hours). We compared the frequency of treatment-related complications among the groups.


Of the 36 patients, 13 had BMI < 30, 18 patients had BMI 30-40, and 5 had BMI > 40, one of whom had BMI > 50 kg/m2. Patients showed improvement in serum creatinine, BUN, phosphorus, potassium, and bicarbonate. All had adequate ultrafiltration and improved volume status after optimization of PD prescription. No differences were observed between groups in achievement of treatment goals. No patients in any group required discontinuation of PD because of treatment-related complications or insufficient dialysis.


Acute PD was successfully performed in obese, and morbidly obese patients during the COVID-19 pandemic. Treatment goals were achieved based on relevant parameters and there were no increases of treatment related complications compared to non-obese patients. Acute PD should not be restricted based on elevated BMI.